OCULAR THERAPEUTIX, INC 8-K
Research Summary
AI-generated summary
Ocular Therapeutix Posts Phase 3 SOL-1 Trial Slides on AXPAXLI
What Happened
Ocular Therapeutix, Inc. (OCUL) filed an Item 7.01 Regulation FD disclosure reporting that, at 4:15 p.m. Eastern on February 27, 2026, it will make available on the Investors section of its website the slides presented at the 49th Macula Society Annual Meeting. The slides contain detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration.
Key Details
- Slides to be posted at 4:15 p.m. ET on February 27, 2026.
- Presentation delivered at the 49th Macula Society Annual Meeting on February 27, 2026.
- Study referenced: SOL-1 Phase 3 superiority clinical trial.
- Drug: AXPAXLI (OTX-TKI), for wet age-related macular degeneration.
Why It Matters
The company is publicly disclosing detailed Phase 3 trial results, making material clinical data broadly available to investors and the market under Regulation FD. Retail investors can review the slides to assess the trial outcomes and better understand the clinical progress of AXPAXLI (OTX-TKI) for wet AMD.